|The CD49d itga4 (Catalog #MBS210989) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s CD49d can be used in a range of immunoassay formats including, but not limited to, Flow cytometry (FC/FACS).
Flow Cytometry: Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Flow Cytometry: Minimum Dilution: Neat; Maximum Dilution: 1/10. Researchers should empirically determine the suitability of the CD49d itga4 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CD49d itga4 product has the following accession number(s) (GI #67191027) (NCBI Accession #NP_000876.3) (Uniprot Accession #P13612). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse anti Human CD49d monoclonal antibody, clone Bu49 recognizes human CD49d, also known as integrin alpha 4 or VLA-4 alpha subunit. CD49d is a 150kDa single pass type I transmembrane glycoprotein. CD49d can be proteolytically cleaved to yield framents of 80 and 70kDa (Hemler et al. 1987). CD49d associates with either CD29 to form VLA-4 or with Integrin beta-7 to form The Peyer patches-specific homing receptor LPAM-1, involved in the lymphocyte migration and homing to gut-associated lymphoid tissue (Sackstein 2006) through its interaction with MadCam-1, preferentially expressed on Peyer\'s patch high endothelial venules and postcapillary venules in lamina propria (Briskin et al. 1997). CD49d is expressed on a broad range of cells including lymphocytes, monocytes, eosinophils and thymocytes. CD49d expression may serve as a prognostic parker of survival and disease progression in patients with chronic lymphocytic leukemia and may have therapeutic potential (Bulian et al. 2008) Mouse anti human CD49, clone Bu49 cross-reacts with the canine B-cell leukemia cell line GL-1 and induces homotypic cell aggregation (Ikewaki et al. 2010).
Perservative Stabilisers: 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
Preparation: Purified IgG prepared by affinity chromatography on Protein G. Buffer Solution: Phosphate buffered saline
Target Species: Human. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD49d are readily searchable from our website. Different antibodies against the same target such as CD49d may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Atherosclerosis, Demyelinating Diseases, Disease Models, Animal, Fibrosis, Inflammation, Leukemia, Lymphocytic, Chronic, B-Cell, Liver Diseases, Lung Diseases, Lung Neoplasms, Necrosis are some of the diseases may be linked to MOUSE ANTI HUMAN CD49d:FITC.